These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 6542338)

  • 21. Prostaglandin E1 in infants with critical congenital heart disease.
    Dungan WT
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1985 Jan; 1(1):71-4. PubMed ID: 2454319
    [No Abstract]   [Full Text] [Related]  

  • 22. Failure of clinical response to prostaglandin E1 in a cyanotic infant with congenital absence of the ductus arteriosus.
    Hamilton WT; Lacina SJ; Bharati S; Lev M; Arcilla RA
    Cathet Cardiovasc Diagn; 1982; 8(3):273-6. PubMed ID: 7201887
    [No Abstract]   [Full Text] [Related]  

  • 23. [Prostaglandins E1 in the treatment of neonatal cardiopathies related to ductus arteriosus. 19 cases].
    Maesen Y; Bosi G; Stijns M; Vliers A
    Arch Mal Coeur Vaiss; 1981 May; 74(5):579-85. PubMed ID: 6794479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostaglandin and damage to ductus arteriosus.
    Moulaert AJ; Gittenberger AC; Harinck E
    Lancet; 1977 Mar; 1(8013):703-4. PubMed ID: 66503
    [No Abstract]   [Full Text] [Related]  

  • 25. [Skeletal side effects of treatment with prostaglandin E1].
    Persigehl M; Hövels-Gürich H; von Bernuth G
    Rofo; 1984 Oct; 141(4):427-30. PubMed ID: 6436918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nursing care of the neonate receiving prostaglandin E1 therapy.
    Rikard DH
    Neonatal Netw; 1993 Jun; 12(4):17-22. PubMed ID: 8510622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anesthesia for neonates and young infants with ductus dependent cardiac malformations treated with prostaglandin E1].
    Fujii S; Nagai I; Yonei A; Sari A; Baba K
    Masui; 1984 May; 33(5):545-9. PubMed ID: 6540818
    [No Abstract]   [Full Text] [Related]  

  • 28. Oral administration of prostaglandin E2 in the hypoplastic left heart syndrome.
    Fujiseki Y; Yamamoto H; Hattori M; Yamawaki Y; Goto M; Shimada M
    Jpn Heart J; 1983 May; 24(3):481-7. PubMed ID: 6576179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of E1 type prostaglandin on hypoxemia in a cyanotic congenital cardiac malformation.
    Moulaert A; Senders R; van Ertbruggen I; Huysmans H; Harinck E
    Eur J Cardiol; 1977 Jun; 5(4):321-5. PubMed ID: 891577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of prostaglandins and blockers of prostaglandin synthesis on the ductus arteriosus: animal and human studies.
    Heymann MA; Rudolph AM
    Adv Prostaglandin Thromboxane Res; 1978; 4():363-72. PubMed ID: 645512
    [No Abstract]   [Full Text] [Related]  

  • 31. Palliation of cyanotic congenital heart disease in infancy with E-type prostaglandins.
    Neutze JM; Starling MB; Elliott RB; Barratt-Boyes BG
    Circulation; 1977 Feb; 55(2):238-41. PubMed ID: 64317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation.
    Huang FK; Lin CC; Huang TC; Weng KP; Liu PY; Chen YY; Wang HP; Ger LP; Hsieh KS
    Pediatr Neonatol; 2013 Apr; 54(2):102-6. PubMed ID: 23590954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of prostaglandins in duct-dependent congenital heart conditions.
    Singh Y; Mikrou P
    Arch Dis Child Educ Pract Ed; 2018 Jun; 103(3):137-140. PubMed ID: 29162633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose prostaglandin E1 is safe and effective for critical congenital heart disease: is it time to revisit the dosing guidelines?
    Vari D; Xiao W; Behere S; Spurrier E; Tsuda T; Baffa JM
    Cardiol Young; 2021 Jan; 31(1):63-70. PubMed ID: 33140712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of prostaglandin E1 infusion in the pre-operative management of critical congenital heart disease.
    Ohara T; Ogata H; Fujiyama J; Murata Y; Abe J; Kakuta K; Hayamizu S; Kameyama S; Yoshida Y
    Tohoku J Exp Med; 1985 Jun; 146(2):237-49. PubMed ID: 4040664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of low dosage prostaglandin--usages and complications.
    Singh GK; Fong LV; Salmon AP; Keeton BR
    Eur Heart J; 1994 Mar; 15(3):377-81. PubMed ID: 8013512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prostaglandin E1 therapy in infants with cyanotic congenital heart malformations: hemodynamic and angiographic findings (author's transl)].
    Schumacher G; Mocellin R; Schöber JG; Kellner M; Bühlmeyer K
    Klin Padiatr; 1978 Sep; 190(5):465-73. PubMed ID: 568198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of prostaglandin E1 on the hemodynamics in newborn infants with pulmonary atresia (author's transl)].
    Mocellin R; Sauer U; Schumacher G; Kellner M; Schöber JG
    Z Kardiol; 1978 Aug; 67(8):572-7. PubMed ID: 695809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations.
    Olley PM; Coceani F; Bodach E
    Circulation; 1976 Apr; 53(4):728-31. PubMed ID: 56243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostaglandin E1 for infants with congenital heart disease.
    Sasso SC
    MCN Am J Matern Child Nurs; 1983; 8(1):29. PubMed ID: 6401340
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.